Feature | July 28, 2014

Boston Scientific Receives CE Mark For Ranger Drug-coated Balloon

Technology strengthens company's portfolio of solutions for peripheral vascular disease

Boston Scientific Corp. CE mark Ranger Ranger Paclitaxel-coated PTA Balloon Cath

July 28, 2014 — Boston Scientific Corp. received CE mark for the Ranger Paclitaxel-coated PTA Balloon Catheter. The technology is now in full European market launch. The Ranger drug-coated balloon (DCB) provides physicians with an additional option to treat peripheral artery disease, delivering an anti-stenotic drug to diseased vascular tissue while leaving no permanent implant behind.

"The Ranger Drug-Coated Balloon offers tremendous promise and will provide another important tool to treat both above-the-knee and below-the-knee lesions," said Dierk Scheinert, M.D., director, Center of Vascular Medicine, Angiology and Vascular Surgery at Park Krankenhaus, Leipzig, Germany. "When using contemporary technologies, a significant amount of drug coating can be lost during the handling, insertion and delivery of the device. I am excited by the technology in the Ranger drug-coated balloon, which has the potential to reduce drug loss significantly while optimizing both deliverability and the absorption of the drug in the targeted tissue."

The Ranger DCB combines the deliverability of the market-leading Sterling balloon platform and the proven drug paclitaxel with advanced technologies designed to address the delicate and often unstable nature of the coating associated with contemporary drug-coated balloons. The Ranger DCB features proprietary TransPax coating technology and an innovative loading tool designed to maintain drug-coating integrity and maximize drug-transfer efficiency resulting in consistent and predictable drug delivery.

For more information: www.bostonscientific.com

 

 

Related Content

Medtronic, In.Pact Admiral drug coated balloon, DCB, FDA approval, 150 mm length
Technology | Drug-Eluting Balloons| July 18, 2016
Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon...
VentureMed Group, Flex Scoring Catheter, FDA approval, peripheral arterial disease, PAD, endovascular treatment
Technology | Catheters| July 13, 2016
July 13, 2016 — VentureMed Group Ltd., specializing in devices for the endovascular treatment of...
News | Drug-Eluting Balloons| June 03, 2016
June 3, 2016 — Cardionovum GmbH recently announced the completion of enrollment of the RAPID trial.
TOBA-BTK study, twelve-month results, SCAI 2016, Tack Endovascular System, critical limb ischemia
News | Peripheral Arterial Disease (PAD)| May 05, 2016
Intact Vascular Inc. announced that positive twelve-month results from its Tack Optimized Balloon Angioplasty – Below-...
ACR, American College of Radiology, MEDCAC, peripheral arterial disease, PAD, seniors
News | Peripheral Arterial Disease (PAD)| April 18, 2016
The American College of Radiology (ACR), as a member of a coalition of leading medical societies, provided peripheral...
Corindus, CorPath Robotic System, FDA clearance, peripheral vascular interventions
Technology | Robotic Systems| March 29, 2016
Corindus Vascular Robotics Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the CorPath...
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter| March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
PinnacleHealth Cardiovascular Institute, TOBA II study, first patient, Tack Endovascular System, PAD
News | Peripheral Arterial Disease (PAD)| March 22, 2016
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania into the TOBA II clinical on Oct. 19...
Boston Scientific, Eluvia vascular stent system, CE Mark, peripheral artery disease
News | Stents Peripheral| March 17, 2016
Boston Scientific announced in late February that the Eluvia Drug-Eluting Vascular Stent System received CE Mark, and...
Overlay Init